PMID- 24565701
OWN - NLM
STAT- MEDLINE
DCOM- 20150102
LR  - 20140225
IS  - 2213-2201 (Electronic)
VI  - 1
IP  - 6
DP  - 2013 Nov-Dec
TI  - Adverse effects of IgG therapy.
PG  - 558-66
LID - S2213-2198(13)00387-5 [pii]
LID - 10.1016/j.jaip.2013.09.012 [doi]
AB  - IgG is widely used for patients with immune deficiencies and in a broad range of 
      autoimmune and inflammatory disorders. Up to 40% of intravenous infusions of IgG 
      may be associated with adverse effects (AEs), which are mostly uncomfortable or 
      unpleasant but often are not serious. The most common infusion-related AE is 
      headache. More serious reactions, including true anaphylaxis and anaphylactoid 
      reactions, occur less frequently. Most reactions are related to the rate of 
      infusion and can be prevented or treated just by slowing the infusion rate. 
      Medications such as nonsteroidal anti-inflammatory drugs, antihistamines, or 
      corticosteroids also may be helpful in preventing or treating these common AEs. 
      IgA deficiency with the potential of IgG or IgE antibodies against IgA increases 
      the risk of some AEs but should not be viewed as a contraindication if IgG 
      therapy is needed. Potentially serious AEs include renal dysfunction and/or 
      failure, thromboembolic events, and acute hemolysis. These events usually are 
      multifactorial, related to combinations of constituents in the IgG product as 
      well as risk factors for the recipient. Awareness of these factors should allow 
      minimization of the risks and consequences of these AEs. Subcutaneous IgG is 
      absorbed more slowly into the circulation and has a lower incidence of AEs, but 
      awareness and diligence are necessary whenever IgG is administered.
CI  - Copyright (c) 2013 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Berger, Melvin
AU  - Berger M
AD  - Immunology Research and Development, CSL Behring, LLC, King of Prussia, Pa. 
      Electronic address: mel.berger@cslbehring.com.
LA  - eng
PT  - Journal Article
DEP - 20131031
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Acute Kidney Injury/etiology/prevention & control
MH  - Anaphylaxis/etiology/prevention & control
MH  - Anemia, Hemolytic/etiology/prevention & control
MH  - Headache Disorders/etiology/prevention & control
MH  - Humans
MH  - Hyponatremia/etiology/prevention & control
MH  - Immunoglobulin A/adverse effects
MH  - Immunoglobulin G/*adverse effects
MH  - Immunoglobulins, Intravenous/*adverse effects
MH  - Meningitis, Aseptic/etiology/prevention & control
MH  - Neutropenia/etiology/prevention & control
MH  - Risk Factors
MH  - Skin Diseases/etiology/prevention & control
MH  - Thromboembolism/etiology/prevention & control
EDAT- 2014/02/26 06:00
MHDA- 2015/01/03 06:00
CRDT- 2014/02/26 06:00
PHST- 2013/08/02 00:00 [received]
PHST- 2013/09/18 00:00 [revised]
PHST- 2013/09/19 00:00 [accepted]
PHST- 2014/02/26 06:00 [entrez]
PHST- 2014/02/26 06:00 [pubmed]
PHST- 2015/01/03 06:00 [medline]
AID - S2213-2198(13)00387-5 [pii]
AID - 10.1016/j.jaip.2013.09.012 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):558-66. doi: 
      10.1016/j.jaip.2013.09.012. Epub 2013 Oct 31.